K. Bernstein

发表

End-Stage Disease: Arresting the Epidemic With the number of patients with end-stage renal disease increasing, renal and dialysis programs must begin promoting renal health and disease pre- vention to encourage early referral for nephrology care.

K. Bernstein, 2002 .

End Stage Renal Disease

K. Bernstein, 2022 .

A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group.

D. Churchill, W. Clark, D. Cattran, 1995, Kidney international.

Erythropoietin-Alpha Dosage Requirements in a Provincial Hemodialysis Population: Effect of Switching from Subcutaneous to Intravenous Administration

L. Vercaigne, C. Raymond, K. Bernstein, 2005, Nephron Clinical Practice.

ANCA Associated Vasculitis Secondary to Levamisole-Adultered Cocaine with Associated Membranous Nephropathy: A Case Series

D. Collister, I. Gibson, M. Karpinski, 2017, American Journal of Nephrology.

Home Hemodialysis in the Remote Canadian North: Treatment in Manitoba Fly‐in Communities

Douglas R. Franklin, P. Komenda, A. Bourne, 2011, Seminars in dialysis.

A Prospective Randomized Trial of Plasma Exchange as Additive Therapy in Idiopathic Crescentic Glomerulonephritis

D. Churchill, D. Cattran, C. Greenwood, 1992 .

A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group.

D. Churchill, W. Clark, D. Cattran, 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Combination Therapy of Intravenous Maxacalcitol and Percutaneous Ethanol Injection Therapy Lowers Serum Parathyroid Hormone Level and Calcium × Phosphorus Product in Secondary Hyperparathyroidism

T. Fujita, T. Fujita, M. Matsushita, 2005, Nephron Clinical Practice.

Antibiotic‐Heparin Lock: In Vitro Antibiotic Stability Combined with Heparin in a Central Venous Catheter

F. Burczynski, D. Sitar, G. Q. Wang, 2000, Pharmacotherapy.

An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters.

S. Penner, L. Vercaigne, S. Zelenitsky, 2002, The Journal of antimicrobial chemotherapy.

Nephrology care in Canada.

C. Rigatto, K. Bernstein, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26.

D. Booth, D. Vigushin, N. Pettigrew, 1994, The Quarterly journal of medicine.

Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.

L. Vercaigne, J. Zacharias, K. Bernstein, 2012, Clinical nephrology.

Type I Gaucher disease following chemotherapy for light chain multiple myeloma.

W. Cheung, C. Greenberg, M. Seftel, 2007, Internal medicine.

Determination of the optimal case definition for the diagnosis of end-stage renal disease from administrative claims data in Manitoba, Canada.

Nancy Xiaonan Yu, N. Tangri, P. Komenda, 2015, CMAJ open.

Model for equitable care and outcomes for remote full care hemodialysis units.

S. Shaw, J. Blanchard, B. Yu, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.

L. Vercaigne, C. Raymond, L. Wazny, 2008, CANNT journal = Journal ACITN.

Secular trends in end-stage renal disease requiring dialysis in Manitoba, Canada: a population-based study.

Nancy Xiaonan Yu, N. Tangri, P. Komenda, 2015, CMAJ open.

Production of tumor necrosis factor alpha and hemodialysis.

D. Rush, R. McKenna, K. Bernstein, 1993, Nephron.